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ABSTRACT   
Introduction: This study examined the effect of a telehealth intervention on the control 
of type 2 diabetes, and subsequent potential cost-savings to the health system. 
Methods: This prospective randomised controlled trial randomised adults with type 2 
diabetes to the intervention (diabetes program) or control (usual care) arm. Key 
eligibility criteria included an HbA1c level of at least 58 mmol/mol (7.5%) without 
severe or unstable comorbidities. All participants continued their usual healthcare, but 
participants in the intervention arm received additional diabetes care from a diabetes 
care coordinator via a home monitor that captured clinical measures. Data collected 
included biomedical, quality of life measures and healthcare (GP, outpatient and 
inpatient) costs. The primary outcome was HbA1c collected at baseline and six-months.  
Analysis was conducted on a complete case intention-to-treat basis. The healthcare 
system perspective was taken to calculate the incremental cost per percentage-point 
reduction in HbA1c. 
Results: Results from 63 participants from each study arm were analysed. HbA1c in the 
intervention group decreased from a median 68 mmol/mol (8.4%) to 58 mmol/mol 
(7.5%), and remained unchanged in the control group at median 65 mmol/mol (8.1%) at 
the six-month endpoint. The intervention effect on HbA1c change was statistically 
significant (p=0.004). Total healthcare costs in the intervention group, including the 
intervention costs, were lower (mean $3,781 vs $4,662; p<0.001) compared to usual 
care.  
Discussion: There was a clinically meaningful and statistically significant benefit from 
the telehealth intervention at a lower cost; thus, telehealth was cost-saving and produced 
greater health benefits compared to usual care.   
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 Introduction 
Worldwide, diabetes is recognised as a growing problem that may threaten global 
development in the future. In Australia, diabetes is the fastest growing chronic disease, 
and is among the top ten leading causes of death.1,2 In 2011-12, 5.1% of Australian 
adults had diabetes, with 90% having type 2 diabetes.3 By 2031, it is projected that 
approximately 10% of the total Australian population may have type 2 diabetes.3 
Since 1997 diabetes has been one of Australia’s National Health Priority Areas due to 
its significant impact on the health of Australians.4 Health planners are concerned that 
the level of chronic and preventable conditions, such as type 2 diabetes, has reached the 
point where the Australian health system can no longer sustain the level of burden of 
disease.5,6 Long-term effects of uncontrolled diabetes increase the burden on the health 
system, with poor glycaemic control significantly increasing the risk of complications 
such as neuropathy, retinopathy, nephropathy, myocardial infarction, stroke and 
amputations.7 
Systematic reviews of telehealth (including telemonitoring) interventions for type 2 
diabetes consistently show positive effects on glycaemic control, with variation in 
effects on other diabetes risk factors e.g. blood pressure, lipids and weight/body mass 
index.8-14 Additionally, people’s quality of life and satisfaction with care appear to 
improve as a result of telemonitoring interventions.10-13  
Large scale programs have shown that the use of telehealth technologies combined with 
a care coordination model of care can be effective in helping people manage their 
chronic health condition. A US study of over 17,000 people enrolled on a home 
telehealth program reported after six months of participation a 20% reduction in 
hospital admissions and 25% reduction in bed days of care over one year compared to 
admissions pre-enrolment.15 People with diabetes in a US Veterans Home Telehealth 
project had a reduction in the overall use of inpatient and outpatient services over the 
48-months follow-up period.16   
The financial benefits from use of telehealth and e-health services are estimated to 
accrue from reduced use of secondary healthcare services, with Access Economics 
estimating the financial benefits of wide-scale telehealth implementation as being 
between $2 billion and $4 billion per year in Australia.17  A recent Australian study 
examining telemonitoring for people with a range of chronic diseases (including 
diabetes) who were frequently admitted to hospital concluded that the return on 
investment of telemonitoring would be between 4.9 and 6.0, resulting from less 
utilisation of hospital and other health services.18 An Australian telehealth randomised 
controlled trial (using an automated interactive telephone intervention in type 2 
diabetes) showed substantially lower healthcare costs modelled over 5 years.19  Reviews 
highlight the need for more evidence into the economic impact of telemonitoring for 
diabetes.10,13,20,21 
 To the knowledge of the authors, no randomised controlled trials testing the use of 
telemonitoring in the management of type 2 diabetes in Australia have been conducted.  
The present study is designed to give high quality evidence on the use, including the 
economic impact, of this health service in Australian primary care, as well as 
contributing to international knowledge.  
 
We hypothesised that a tailored telemonitoring intervention could result in better control 
of diabetes and reduced utilisation of health services. The study, named Townsville 
Broadband Diabetes Telehealth (TBDT) trial, examined the effect of a telemonitoring 
intervention based in primary care on the control of type 2 diabetes at 12 months 
following the intervention, and subsequent cost-savings to the health system.  
 
Methods 
Study Design 
The study was a two-arm prospective randomised controlled trial in which adults with 
type 2 diabetes were randomised to the intervention (diabetes program) or control (usual 
care) arm and was conducted in a primary health setting in a regional city in 
Queensland, Australia.  The study was conducted with the cooperation of 25 general 
practices which were the usual practices participants attended for their diabetes care.   
 Participants 
Participants in the study were people living with type 2 diabetes in the Townsville area.  
Inclusions and exclusions for the trial are defined in Table 1.  The primary recruitment 
method was via general practices, and general practitioner(GP) agreement to be 
involved in the study as the participant’s GP was sought before participant enrolment 
was finalised. Practice staff identified potential participants through their diabetes 
registers and contacted them to gauge interest in participation. The study team then met 
in person those individuals who expressed interest, gave full information and obtained 
informed written consent. If a recent HbA1c result (within the last three months) was not 
available, a blood test was requested to confirm eligibility. Additional recruitment 
strategies were also used, including liaison with other health clinics, participation at 
community events, distribution of leaflets and posters, display equipment at health 
services, and advertisements in GP and consumer publications. 
Randomisation and masking 
Arm allocation was conducted with the participant as the unit of randomisation, using 
computer-generated 1:1 simple randomisation.  The random allocation sequence was 
generated by the study research coordinator (KC), held in a secure opaque envelope by 
the study administrator and concealed to the study Care Co-ordinators (CCs).  CCs 
consented participants and contacted the study administrator for group assignment.  Due 
to the nature of the intervention, participants, health professionals and researchers were 
not blinded to trial arm allocation. 
Procedures  
All participants were asked to continue their usual health care which may have included 
general practice, specialist and allied health involvement. CCs conducted home visits 
for all participants at baseline, six months and 12 months to gather clinical data (blood 
pressure, random blood glucose, weight, height, waist circumference, foot health) and 
complete questionnaires. All pathology for the study was conducted at laboratories 
through usual referral mechanisms used by general practice. CCs were nurses with 
practice nurse experience, and chronic disease management and health coaching 
training. GPs continued to manage their participants’ care, in partnership with CCs. The 
intervention delivered by the CCs is described in Table 2 and was consistent with the 
RACGP/Diabetes Australia type 2 diabetes guideline.22 CCs provided regular reports to 
participants’ GPs, and were in communication with the GPs if there was clinical need. 
Consistency of the intervention delivered by two CCs was maintained through 
adherence to trial protocols and regular clinical meetings. 
Outcomes 
The primary clinical outcome was HbA1c expressed as %; secondary clinical outcomes 
were a range of biomedical measures (blood pressure and test results, etc.) including 
depression, frequency of health services use (e.g. GP consultations, specialist visits, 
admissions to hospital) and costs.  Participant satisfaction and technology acceptability 
measures were also collected, and results of these outcomes will be reported in a future 
paper.  Participant data were collected by GPs and CCs at baseline and follow-up. On 
study completion, data were collected from GPs and public hospital records on deaths, 
details of hospital admissions, referrals to medical specialists, and number of visits to 
the GP. Participants were surveyed at baseline and follow-up using a quality of life 
questionnaire (SF-12) and a depression screening questionnaire (K10).23,24 The research 
team collected data on trial set-up, operational and intervention costs. For the purposes 
of calculating adherence and intervention costs, frequency and length of participant/CC 
use of the telemonitoring equipment were captured automatically by the monitoring 
system.  Participation in intervention aspects not recorded by the monitoring system 
(e.g. telephone calls, home visits) were registered by CCs in the system’s participant 
record.  Copies of participant records were extracted monthly for review of accuracy by 
the CCs.  Detailed timesheets of workflow for CCs were maintained for fortnightly 
periods at three time points in the study period to calculate staff costs.  
 
Safety concerns and adverse events were monitored through a CC weekly clinical 
review.  Any suspected concerns were reported to the participants’ GPs.  Additionally, 
the study’s Clinical Advisory Group met regularly to confirm the clinical conduct of the 
intervention and respond to clinical issues and safety. 
 Statistical analysis 
Initial power calculations showed that assuming an attrition rate of 30% over 12 
months, an intervention effect of at least a 5 mmol/mol (0.4%) reduction in HbA1c 
would be able to be detected with 80% power and type I error of 5% (two-tailed) from 
complete data on 210 participants.25,26 During the course of the trial, significant delays 
in the roll-out of high-speed internet connections affected recruitment strategies and 
progress of the trial.  To ensure completion of the study within timeframes required by 
funders, the target was adjusted to ensure six months follow-up from all participants as 
previous evidence had shown that positive effects could be expected in this time. The 
sample size target was decreased to 120 participants, based on evidence that a larger 
effect can be expected.27 Enrolment in the study closed when this sample size was 
achieved. 
Analyses were conducted on a complete case intention to treat basis. 
Missing values of HbA1c at 6 months were replaced with the 3 months’ observations 
(last observation carried forward).  Missing cost outcomes for participants who were 
lost or withdrew after randomisation were not imputed. Analysis of covariance 
(ANCOVA) models were fitted to investigate the effect of study arm on the outcome 
measures. Possible confounding by baseline characteristics was also explored. Residual, 
DFBETA and Cook’s distance graphs were checked. Sensitivity analyses were 
performed with influential observations excluded from analysis. Differences in 
secondary clinical outcomes between groups were explored using ANCOVA models or 
logistic regression. Stata 13.1 was used for statistical analysis. To be considered as 
statistical significance, p-values at <0.05 were used.  
 
Economic analysis 
Cost-effectiveness was assessed from a healthcare system perspective using participant-
level data from the trial. The cost of healthcare utilisation was calculated for the trial 
period by summing the cost of visits to GPs, specialists and hospital admissions. 
Hospital events were categorised as diabetes-associated or all other-cause events. 
Length of stay data, where missing, was replaced with the mean length of stay for that 
diagnosis-related group (DRG) item. The costs of private hospital admissions were 
replaced with the mean cost of the DRG item considering the observed length of stays. 
The average daily cost of the intervention per participant was calculated; this included 
recruitment, set-up, health assessments, CC consultations, monitoring and triage, 
software maintenance, internet connection, reports and communication with other health 
professionals, and equipment removal. An alternative daily cost value was calculated 
assuming a fully implemented service, and used for sensitivity analyses. All costs were 
converted to 2013 dollars using the Australian Consumer Price Index. Costs were 
compared between groups using the non-parametric median test. The incremental cost-
effectiveness ratio (ICER) was calculated as the difference in costs divided by the 
difference in mean HbA1c results for the two strategies. The 95% credible interval for 
the ICER was estimated by bootstrapping the results with 1,000 simulations. Sensitivity 
analyses were undertaken for key parameters with uncertainty and/or variability. 
 
Ethical approval for the trial was received from the Royal Australian College of General 
Practitioners National Research and Evaluation Ethics Committee (11-006) and the 
Griffith University Human Research Ethics Committee (MED/07/12/HREC).  The trial 
protocol has been published in 2012.25  The trial was registered with the Australian New 
Zealand Clinical Trials Registry (ACTRN12612000086864). 
 
 
 
Results 
Recruitment was conducted from 1 February 2012 to 20 June 2014. A total of 157 
individuals were randomised.  Of these, 31 participants were lost to follow-up of which 
19 were unable to participate in the study (Figure 1).  This was primarily due to a long 
time interval between consent and intervention commencement forced by the 
availability of internet connections, and resultant changes in participant circumstances 
(e.g. medical status, residential address) for 17 participants allocated to the intervention.  
Follow-up data were collected and analysed from 126 participants (Figure 1). 
Participant characteristics at baseline are presented in Table 3. Participants in the two 
arms were similar in age distribution, indigenous and marital status, but there were 
slightly more men in the intervention group compared to the control group (38/63 vs. 
30/63, respectively). 
Participants were engaged in the study over the period from March 2012 – November 
2014, and followed for a median duration of 6.9 months (range: 4.4 to 14.4). 
Intervention participants nominated 51 GPs from 19 general practices as their usual GP, 
while control participants identified 41 GPs from 20 practices. Three quarters (75%; 
n=47) of participants in the intervention arm engaged in the monitoring aspect of the 
intervention at levels recommended by the CCs or above, while 62% (n=39) engaged in 
the CC consultation aspect of the program at or over the minimum recommended level.   
Baseline and follow-up levels of the clinical and quality of life outcomes are presented 
in Table 3. Baseline values were at similar levels in the study groups, except the median 
values of albumin creatinine ratio and nephropathy were approximately 35% lower in 
the intervention group at baseline. The change in clinical and quality of life outcomes 
over time was mostly similar across the study groups, except the change (reduction) in 
HbA1c values in the intervention group over time was significantly greater than in the 
control group (p<0.01): median difference 9.5 mmol/mol (Table 3), mean difference 8.0 
mmol/mol (calculated). For the cost-effectiveness calculation, the difference in HbA1c 
(%) values between study groups was expressed as the difference in mean values at 
follow-up: -0.305 (calculated). Post-hoc assessment of the results for the intervention 
group (two samples of n=63, repeated measures, ANCOVA analysis) estimated the 
power at 82%. 
The changes in secondary outcome measures (biomedical, depression and quality-of-
life) were neither clinically nor statistically significant (Table 3).  There were no 
adverse events or deaths during the study period. 
The overall healthcare utilisation cost was lower (p=0.022) in the intervention group 
(median: $667; IQR: 376-1,197; mean $1,906) than in the control group ($861; 623-
1,782; $4,662), due to fewer visits to GPs, referrals to specialists and hospital 
admissions in the intervention group (Table 4). After including the cost of the 
intervention ($1875), the difference in mean costs between groups, required for cost 
effectiveness calculation, (mean intervention group costs minus mean control group 
costs) was significant ($3,781-$4,662= -$881; p<0.001). The Incremental Cost 
Effectiveness Ratio (ICER, -881/-0·305=) was 2,889, which shows the cost difference 
per percentage-point change in HbA1c. The intervention is the dominant strategy as this 
was cost saving and had greater health benefits (i.e. lower HbA1c) compared to usual 
care. Bootstrapped estimates of cost and HbA1c differences showed on the cost-
effectiveness plane as a scatterplot of the simulations indicate that the results 
corresponded with an intervention associated with reduced HbA1c values and lower 
healthcare utilisation costs (Figure 2). The mean difference in costs and HbA1c is the 
diamond in the centre of the 95% credible ellipse.  The intervention was cost-saving in 
74% of the simulations (i.e. points below the $0 horizontal incremental cost line) and 
reduced HbA1c in 87% of the simulations (i.e. points to the left the vertical line at 0.0 
on the HbA1c difference axis).  Results of sensitivity analyses (Table 5) indicated that 
the intervention remained more effective and less costly across all sensitivity conditions 
explored. 
Discussion 
The TBDT trial showed that a positive effect on glycaemic control resulted from 
participation in a telemonitoring intervention, when compared to usual care.  
Additionally, this was accompanied by a decrease in the healthcare costs from GP visits, 
specialist referrals and hospital admissions.  There was no significant association found 
between changes in secondary outcomes and study group.  
The reduction of mean HbA1c in the intervention group over six months by 8 mmol/mol 
is comparable to other therapeutic interventions. It is also considered clinically 
significant as research from the United Kingdom Prospective Diabetes Study showed 
that there is a direct relationship between glycaemic level and risk of complications; for 
example, a 1% lower mean HbA1c was associated with a 21% reduction in deaths 
related to diabetes, a 14% reduction in myocardial infarction and a 37% reduction in 
microvascular complications.7 
Healthcare costs were significantly lower in the intervention group (mean difference: 
$4,662-$1,906= $2,756; Table 4) compared to the control group. This result excluded 
the cost of intervention ($1,875) applicable in the intervention group; after accounting 
for this cost, the intervention is clearly cost-saving (net mean cost-savings of $881 
(4,662-3,781; Table 5) per participant in a six-month period). Efficiency gains (expected 
after implementation as standard practice) are likely to further decrease the cost of 
intervention. Of note is that a small number of control group participants incurred 
relatively high costs (n=8 had costs >$10,000, max $47,500) but many had zero or low 
costs, whereas in the intervention group, all incurred the minimum cost of the 
intervention ($1,875) but n=5 incurred costs >$10,000 (max $23,000). These 
distributions of costs explain the differences between mean and median costs in the 
groups.  The set-up costs of a telemonitoring system which are additional to the costs 
used in the analysis would impact on the feasibility of providing the intervention 
initially. However, by providing the intervention at scale and on an ongoing basis, the 
cost of provision would be offset by the reduction in healthcare resource utilisation 
costs. 
The trial’s results are consistent with previous published telehealth interventions.  A 
recent review of interventions most similar to the present study13 (telemonitoring for 
adults with type 2 diabetes) concluded that 15 out of 19 studies reviewed showed 
positive impacts on HbA1c.    The lack of effect on secondary clinical outcomes is 
similarly consistent, with trials reporting mixed effects on these indicators.10,13  Quality 
of life did not show significant change in our study, with trials overall showing no 
change or positive effects on this indicator.11  
The results, in respect to health system use and cost, add to the current evidence in 
Australia of benefit from the implementation of home telemonitoring.  A national multi-
site trial in older people with chronic disease also found reductions in hospital and 
primary care costs.18   This trial involved participants who were at higher risk of hospital 
readmission (assessed on their rate of previous admission).  Of interest comparatively, 
our trial was able to demonstrate cost-effectiveness in a group of people of younger 
average age, selected on the basis of disease(glycaemic) control, rather than risk of 
hospitalisation.   Internationally, the reduction of inpatient and outpatient costs has 
previously been reported as a result of a large scale home telehealth study.15,16 
 
Limitations of the present study included the reliance on data from six months of 
participant follow-up, compared with the planned 12-month study period; and the 
failure to reach initial target participant numbers. Nevertheless, post-hoc power analyses 
showed the study sample size was adequately powered for the variance around the 
effect size with a power of 82%.  Additionally, data were sourced from general practices 
which may have compromised the quality of information relating to health care outside 
of the general practice setting, particularly in outpatient and private hospital admissions; 
however, this is typical of the population living with diabetes as patients are generally 
managed on a day-to-day basis by their general practitioner in primary care.  Potential 
selection bias may have been present in this trial from factors including the likelihood 
that people willing to enrol and participate were possibly more likely to show 
behaviours that increased their wellbeing; additionally, general practices were involved 
in presentation of the study to potential participants and may have selected patients for 
their perceived suitability. However, these participants are likely to have been randomly 
and equally assigned across both groups.  
Overall, the study collected comprehensive healthcare utilisation information and cost 
data from the primary and secondary care sectors to undertake a comparative 
effectiveness analysis. The intervention was effective in reducing HbA1c levels, shifting 
patients with diabetes from being poorly controlled to having good control and 
significantly reducing the costs of inpatient and outpatient resources.  
These results provide evidence of the applicability of telemonitoring to Australian 
settings which may be expanded to primary care settings in other jurisdictions. Ideally, 
the intervention would be suitable to be tested with a larger sample and assessed for its 
impact across the spectrum of diabetes severity. Additionally, the durability of the 
intervention’s effect should be studied to predict the long term impact possible, as well 
as investigating the most efficient methods for implementation, in terms of cost, 
effectiveness and integration into current health systems.  
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 Table 1.    Inclusion and exclusion criteria 
Inclusions 
Diagnosis of type 2 diabetes mellitus 
HbA1c level measured at ≥ 58 mmol/mol (7.5%) at least once in the previous 12 
months 
Aged 18 years or older 
Living in own home (i.e. not in residential care) in Townsville, Queensland, 
Australia) 
Access to high-speed broadband internet (fixed-line fibre-optic or copper cabled) 
Under primary care of general practitioner (GP) for diabetes management 
Exclusions 
Pregnancy or diagnosis of gestational diabetes 
Severe unstable comorbidities with likely poor prognosis within 12 months 
Cancer (except non-melanotic skin cancer) 
Dementia, intellectual or mental impairment (that would preclude use of 
technology) 
Chronic kidney disease where renal dialysis is required or likely within 12 months 
Severe vision impairment (with inability to use technology) 
Enrolment in another health intervention trial 
Primary language other than English 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Trial Intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Components of the intervention 
 
 
Initial home visit 
(a second follow-up 
visit was offered, if 
further training, 
assessment or 
support was required 
by participant) 
 
Equipment set-up and 
training  
 
 
 
 
 
 
Participants received home telehealth devices, consisting of 
• Tablet computer (ASUS®,Lenovo®) with vital sign monitoring software (Tunstall myclinic®), 
videoconferencing software (Tunstall ICP videoconferencing®), health questionnaires, educational videos, 
information sheets 
• Bluetooth-compatible blood pressure monitor (A&D Medical®, Omron®) 
• Bluetooth-compatible glucometer (MyGlucoHealth®) 
 
 
Blood glucose and blood 
pressure monitoring 
 
 
 
Participants were asked to monitor blood glucose (pre- and postprandial) and blood pressure at least three times 
weekly, as a general minimum level  
 
 
Assessment and care plan 
 
 
 
A holistic diabetic health assessment, including medical and social history, medication use, mental health status and 
lifestyle practices, was performed.  
A care plan and patient-centred goals, using the general practitioner’s management plan as a base, was developed in 
accordance with Australian type 2 diabetes guidelines. 
 
CC consultation 
 
CCs discussed availability of role for support and consultation and encouraged participants to use videoconferencing 
as the prime method of communication. 
 
Ongoing support 
 
Blood glucose and blood 
pressure monitoring, 
health questionnaires. 
 
 
 
Measurements and health questionnaire responses were sent from the tablets via the internet to a central computer 
running monitoring software (Tunstall ICP triage manager®).  Data collected were checked by CCs daily and CC 
response, based on individual clinical need and guided by trial developed protocols sourced from international and 
national guidelines.  
 
 
CC consultation 
 
At least once monthly consultations on monitoring results, progress towards goals/ development of new goals, health 
education and development of self-management strategies.   
 
Final home visit 
 
Equipment removal and 
intervention conclusion 
 
 
Advice on how to access future support was discussed. 
 
Table 3. Participant characteristics and study outcomes 
Participant characteristics at baseline 
 Intervention n=63 
Control  
n=63  
Age (years, in 2014)a 61.3 (10.8) 61.3 (11.4)  
Sex: men 38 (60%) 30 (48%)  
ATSI: yes 8 (13%) 9 (14%)  
Partnered: yesb 40 (77%) 40 (77%)  
frequencies and column percentages shown unless otherwise noted;  a mean (standard deviation) 
shown; b responses to this question were received from 104 participants; ATSI = Aboriginal or 
Torres Strait Islander; 
Study outcomes at baseline and follow-up 
 T Intervention n=63 
Control  
n=63 p-value 
HbA1c (mmol/mol) B 67.5 (62.0-75.0) 64.5 (54.0-74.0) - 
 6 58.0 (53.0-68.0) 65.0 (57.0-74.0) 
HbA1c (%) B 8.4 (7.8-9.0) 8.1 (7.1-8.9) 0.004a 
 
6 7.5 (6.9-8.2) 8.1 (7.4-8.9) 
Cholesterol level, total mmol/L B 4.0 (3.2-4.8) 4.0 (3.4-4.7) 0.566 
 
6 4.3 (3.6-4.9) 3.9 (3.4-4.8) 
Blood Pressure (systolic), mmHg B 130.0 (117.0-139.0) 126.0 (119.0-139.0) 0.072 
 
6 126.0 (115.0-138.0) 134.0 (119.0-145.0) 
Blood Pressure (diastolic), mmHg B 82.0 (75.0-88.0) 80.0 (70.0-86.0) 0.502 
 
6 83.0 (73.0-87.0) 84.0 (74.0-88.0) 
Random Blood Glucose, mmol/L B 10.4 (7.3-13.2) 9.6 (7.5-13.4) 0.969 
 
6 9.4 (7.1-11.4) 8.8 (7.2-13.1) 
Creatinine serum level, mmol/L B 76.0 (65.0-89.0) 76.5 (69.0-94.0) 0.618 
 
6 72.0 (61.0-86.0) 72.0 (63.0-87.0) 
eGFR, mL min-1 1.73 m-2 B 87.0 (72.5-90.0) 84.5 (68.0-90.0) 0.857 
 
6 90.0 (80.0-90.0) 86.5 (76.0-90.0) 
Albumin creatinine ratio B 0.9 (0.5-3.3) 1.4 (0.5-5.6) 0.122 
 
6 1.6 (0.5-9.6) 2.0 (0.7-8.7) 
Waist circumference, cm B 111.0 (106.0-128.0) 113.0 (100.0-126.0) 0.949 
 
6 112.0 (102.0-122.0) 113.0 (99.0-126.0) 
Weight, kg B 95.8 (82.0-116.5) 97.1 (82.2-115.9) 0.657 
 
6 95.6 (81.2-118.4) 96.8 (78.9-115.1) 
Body mass index, kg/m2  B 34.2 (29.6-39.8) 34.1 (30.3-40.6) 0.507 
 
6 34.5 (30.3-39.6) 33.6 (29.5-38.4) 
Clinical depression score (K10) B 15.5 (13.0-25.0) 16.0 (14.0-23.0) 0.147 
 
6 14.5 (11.0-22.0) 18.0 (12.0-22.0) 
Nephropathy B 8 (19%) 13 (34%) 0.412 
 
6 8 (26%) 13 (39%) 
Neuropathy B 25 (40%) 21 (33%) 0.492 
 
6 22 (37%) 22 (39%) 
Renal failure B 1 (2%) 1 (2%) ^ 
 
6 0 (0%) 1 (2%) 
Foot ulcer B 2 (3%) 1 (2%) 0.447 
 
6 1 (2%) 2 (4%) 
Amputation B 1 (2%) 2 (3%) ^ 
 
6 1 (2%) 2 (3%) 
Death B n/a n/a 
^  6 0 (0%) 0 (0%) 
 6 1.90 (1.15) 2.07 (1.07) 
SF-6D index score B 0.65 (0.09) 0.66 (0.08) 0.896 
 6 0.65 (0.08) 0.65 (0.09)  
T = timepoint; B = baseline; 6 = 6 months follow-up; p-values (null hypothesis: no difference in 
observed changes between groups) calculated with analysis of covariance or logistic regression; a 
adjusted for body-mass index at baseline; eGFR = estimated glomerular filtration rate; K10 = 
Kessler psychological distress scale; HbA1c = glycated haemoglobin; Neuropathy = any loss of foot 
sensation on 10-point microfilament test; Renal failure = presence of chronic kidney disease Stage 
4 or 5, as indicated by eGFR<30mL/min/1.73 m2; Nephropathy = albumin/creatinine ratio  ≥ 2.5 
males, ≥ 3.5 females;  n (%) or median and inter-quartile range presented unless otherwise noted; 
frequencies may not add up to group size due to missing data; % proportions calculated with 
number of non-missing values in denominator; ^ = cannot be calculated; n/a = not applicable; - = 
not calculated; 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Cost and effectiveness outcomes 
 Intervention Control 
 median (IQR) mean (SD) median (IQR) mean (SD) 
GP visits     
- number 6 (4-9) - 9 (5-15) - 
- cost $513 (265-965) $639 (484) $718 (405-1,197) $828 (545) 
Specialist visitsa     
- number 1 (0-3) - 2 (1-3) - 
- cost $73 (0-218) $116 (131) $146 (73-218) $154 (176) 
Hospital admissions     
- number  0 (0-0) 0.37 (1.47) 0 (0-1) 0.44 (0.96) 
- diabetes related - 43% - 50% 
- days of stay 0 (0-0) 0.90 (3.43) 0 (0-1) 1.78 (5.80) 
- cost $0 (0-0) $1,112 (3,798) $0 (0-504) $3,802 (9,234) 
- diabetes related cost  $0 (0-0) $467 (1,863) $0 (0-0) $1,390 (5,394) 
Healthcare util. costb $667 (376-1,197) $1,906 (4,126) $861 (623-1,782) $4,662 (9,642) 
Intervention costc $1,875 $1,875 $0 $0 
Total cost $2,542 (2,251-3,072) $3,781 (4,126) $861 (623-1,782) $4,662 (9,642) 
a based on referrals during trial; b excluding intervention costs; c same for every participant, therefore 
spread of values (IQR or SD) are not shown; util. = utilisation; IQR = inter-quartile range as 25th-75th 
percentiles; costs reported in 2013 Australian Dollars; GP = general practice; SD = standard 
deviation; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5. Cost-effectiveness sensitivity analyses 
 ICER by group 
 Intervention Control 
Healthcare utilisation variations:   
- cost of GP visits lower by 30% 4,060 2,615 
- cost of GP visits greater by 30% 2,808 4,253 
- cost of specialist visits lower by 30% 3,548 3,284 
- cost of specialist visits greater by 30% 3,320 3,584 
- cost of hospitalisations lower by 30% 4,528 -305 
- cost of hospitalisations greater by 30% 2,340 7,173 
Intervention cost variations:   
- lowered by 30% 5,278 3,434 
- increased by 30% 1,590 3,434 
ICER = incremental cost-effectiveness ratio, calculated as cost-
difference (over 6 months, intervention minus control) between 
groups divided by the effectiveness-difference (HbA1c % at 6 
months, intervention minus control); 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.  Trial CONSORT flow diagram 
 
 
 
 
 
  
 
